Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

[2] To date, there are few prospective clinical trials of neoadjuvant targeted therapy in patients with ALK-positive locally advanced NSCLC. [...]the value of ceritinib in ALK-positive stage IIIA (N2) NSCLC is unknown. [...]the fluorodeoxyglucose metabolism was also reduced in January 2022, considering the tumor activity was basically inhibited [Figure 1E]. [...]the patient was considered down-staged to clinical complete response (CR) after 7 cycles of ceritinib treatment. [...]this study reported a case of stage IIIA-N2 ALK-positive NSCLC patient treated with ceritinib which illustrated the feasibility and remarkable clinical efficacy of ceritinib as neoadjuvant targeted therapy.